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The increasing incidence of gastrointestinal tract pathologies in dogs and the worrisome
topic of antibiotic resistance have raised the need to look for new therapeutic
frontiers. Of these, the use of probiotics represents a potential therapeutic alternative.
Lactobacillus kefiri (Lk) is a species of Lactobacillus isolated from kefir. Previous studies
have demonstrated that its administration in mice downregulates the expression of
proinflammatory mediators and increases anti-inflammatory molecules in the gut immune
system. It also regulates intestinal homeostasis, incrementing immunoglobulin A (IgA)
secretion. Since Lk has never been studied as a single probiotic in dogs, the aim of this
study was to evaluate the safety of Lk in dogs, and its effect on IgA secretion and on
intestinal microbiota composition. Ten healthy dogs without a history of gastrointestinal
diseases were included. The dogs received Lk at a dose of 107 live microorganisms
orally, once daily for 30 days. The fecal samples were tested before administration, in the
middle, at the end, and 30 days after discontinuation. The IgA secretion concentration
and the microbiota composition were evaluated on the fecal samples. The results in
this study suggested that Lk did not influence the concentration of IgA, nor significant
changes of the intestinal microbiota were observed during and after the treatment.
Therefore, additional studies are needed to investigate if a higher daily dosage of Lk
can influence the intestinal homeostasis of dogs.
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INTRODUCTION
In recent years, intestinal microbiota has become increasingly relevant for veterinary scientists
and has been studied for its role on the welfare of the host (1). It is an ecosystem including
mainly bacteria, but also archaea, fungi, protozoa, and viruses, which plays several roles in the host
physiology by means of a range of metabolic and immunological interactions. In fact, this complex
ecosystem helps in the digestion of food by assisting the absorption and metabolism of nutrients,
and has trophic and protective functions (2). It defends the gastrointestinal tract (GIT) against
pathogenic organisms, promotes mucus production and enterocyte turnover, and modulates host
immune development and functionality (3). In particular, commensal bacteria provide intestinal
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immune protection by regulating, among other things, the
secretion of IgA, the lack of which seems to be correlated with
chronic enteropathies in dogs (4, 5).
Canine chronic enteropathies, categorized into four classes
(food responsive; antibiotic responsive; immunosuppressant
responsive; nonresponsive enteropathy) according to the
response to treatment, are multifactorial diseases where host
genetic factors, the immune system, and indigenous intestinal
bacteria are supposed to be engaged in intricate interactions
(6, 7).
Dogs affected by antibiotic responsive enteropathy (ARE)
are generally young, predominantly belong to large breeds,
and show remission of clinical signs following antimicrobial
administration (metronidazole, tylosin, doxycycline, rifaximine)
(8, 9). It is thought that antimicrobials are able to modify the
intestinal microbial population by counteracting its imbalances
(i.e., dysbiosis); however, although a short-term response to
metronidazole and tylosin has been reported, very few papers
have described the long-term control of ARE (9–11).
Moreover, there is now evidence that prolonged treatment
with antibiotics, particularly with metronidazole, can lead to
permanent unfavorable changes in the microbiota, promoting
antimicrobial resistance, currently one of the most important
threats to public health (12, 13).
Therefore, the increasing incidence of GIT pathologies and the
worrisome topic of antibiotic resistance create the need for new
therapeutic options (14), and toward replacing antibiotics with
(a) probiotics (live microorganisms that confer a healthy benefit
on the host); (b) prebiotics (a substrate selectively utilized by host
microorganisms useful for reestablishing a eubiotic microbiota
layout); (c) synbiotics (a mixture of probiotics and prebiotics
having a synergistic action on host health); and (d) postbiotics
(soluble factors or metabolic byproducts, secreted by live bacteria
or released after bacterial lysis expressing biological activity in
the host).
Lactic acid bacteria (LAB), including Lactococcus,
Streptococcus, Enterococcus, Pediococcus, Leuconostoc, and
Lactobacillus, are probiotic bacteria that are normally part of the
intestinal microbiota of dogs and cats (2). Lactobacillus species
are distributed throughout the canine intestinal tract in varying
amounts (2). Several strains of Lactobacilli have specifically been
studied for their ability to reduce the number of pathogenic
bacteria in the canine intestine (15–20).
Among different naturally fermented foods and their potential
probiotic properties, particular attention has recently been
focused on kefir, a dairy product that could modulate canine
intestinal microbiota if given regularly (21). Kefir has a complex
composition of microbial organisms, which includes several
species of LAB as well as acetic acid bacteria and yeast (22).
Lactobacillus kefiri (Lk) is a Lactobacillus species that has been
isolated from kefir (23). Previous studies have demonstrated
that its administration in mice downregulates the expression
of proinflammatory mediators and increases anti-inflammatory
molecules in the gut immune system (24, 25). It also regulates
intestinal homeostasis by increasing IgA secretion and mucin
production (25). Probiotic properties of Lk have also recently
been demonstrated in humans (26); however, to the best of
the authors’ knowledge, the use of Lk has never been evaluated
in dogs.
The aim of this study was to evaluate the safety and ease of
administration of Lk in healthy dogs and its ability to impact the
intestinal microbiota composition and IgA secretion.
MATERIALS AND METHODS
Lactobacillus kefiri Administration
This study is based on the use of a commercial food supplement
(Kefibios R©), provided by the company Hulka S.r.L. (Rovigo,
Italy), containing live lactic ferments of Lk (LKF01–DSM 32079),
currently used as probiotics in human medicine. Copyright
permission to publish the product name (Kefibios R©) was given
by the Chief Executive Officer of Hulka S.r.L. The product is
marketed in capsules. Following the label of the product, five
drops of the solution reconstituted with 6ml of vegetable oil in
prefilled bottles contain ≥109 active fluorescent units (AFUs)
of live and viable Lk (ISO 19344:2015). The dose corresponds
to the human one indicated by the company, regardless of age
and body weight (BW). The study, involving 10 healthy privately
owned dogs, was conducted at the Veterinary Teaching Hospital
(VTH) of our department. The owners were carefully instructed
as to how to use and mix the product, and then shake the bottle
before each administration. The product was then stored at room
temperature between 10◦C and 25◦C and away from direct light.
The recruitment of the dogs in the study was voluntary and
at no cost to the owners. Written informed consent before
enrollment in the study was obtained from the owners.
The trial was authorized by the Animal Welfare Committee of
the University of Bologna (Protocol No. 3885 of 21/07/2017).
Animals and Experimental Design
Privately owned dogs of various breeds, genders, and weight, over
1 year of age, were enrolled in the trial. Dogs with any disease in
the previous 2 months before the start of the trial were excluded.
The inclusion criterion was the absence of antimicrobial or
immunosuppressive treatment up to 60 days prior to the start of
and during the trial. For inclusion, each dog was evaluated with
a clinical examination and a laboratory panel, which included
a complete blood count, a serum biochemistry profile, and
coprological examination for gastrointestinal parasites.
The body condition score (BCS) was calculated using the 1–
9 score proposed by Royal Canine SAS, and the fecal score was
evaluated according to the Fecal Score System (FSS 1-7) proposed
by Nestlé-Purina Petcare. The BCS was determined as follows:
1–3 = too thin, 4–5 = ideal, and 6–9 = too heavy. The fecal
samples were scored as follows: 1 = very hard and dry, leaves
no residue on the ground when picked up; 2 = firm, but not
hard, pliable, little or no residue on the ground when picked up;
3 = log-shaped, moist surface, leaves residue on the ground, but
holds form when picked up; 4 = very moist and soggy, leaves
residue on the ground and loses form when picked up; 5 = very
moist but has a distinct shape, leaves residue on the ground and
loses form when picked up; 6= has texture, but no defined shape,
leaves residue on the ground when picked up; and 7= watery, no
texture, present in flat patches.
Frontiers in Veterinary Science | www.frontiersin.org 2 April 2020 | Volume 7 | Article 146
Gaspardo et al. Effect of Lactobacillus kefiri on Canine Gut
TABLE 1 | Dogs included in the study.
Dogs Breed Gender Age Weight BCS Fecal score Diet
1 Mix breed C 4y1m 33 kg 6 2 Purina tonus dog chow chicken
2 Mix breed S 4y0m 18.3 kg 6 2 Purina tonus dog chow chicken
3 Border Collie F 2y6m 19 kg 4 2 Prolife adult medium chicken and rice
4 Australian shepherd S 6y0m 23 kg 5 2 Royal canin veterinary diet neutered adult medium dog
5 Border Collie C 2y6m 20.5 kg 5 2 Farmina ancestral low grain lamb and blueberry
6 Dachshund F 3y4m 5.6 kg 6 2 Royal canin small dog chicken and rice
7 Border Collie S 9y7m 19 kg 5 2 Prolife adult medium chicken and rice
8 Labrador retriever M 2y5m 32.1 kg 5 3 Monge natural superpremium rabbit, rice, and potatoes
9 Mix breed S 9y8m 7.5 kg 5 3 Royal canin small dog chicken and rice
10 Mix breed C 5y11m 5.7 kg 5 2 Royal canin small dog chicken and rice
M, male; C, neutered male; F, female; S, neutered female; BCS, body condition score.
Not being experimental animals but privately owned dogs,
diet was not standardized during the trial but the previous diet
(Table 1) was maintained, and water was supplied ad libitum.
During the entire experimental time, the dogs received five
drops (≥109 AFUs) of Lk once daily for 30 days, administered
directly in the mouth during the dinner meal.
Clinical examination, BCS, and FSS were performed at
inclusion, and, during the trial, respectively, 15, 30, and 60 days
after the start of Lk administration.
Samples of fresh feces were collected from each dog on three
consecutive days: (a) at T0, before the start of Lk administration
(days −3, −2, −1); (b) at T15, in the intermediate time of Lk
administration (days 13, 14, 15); (c) at T30, at the end of Lk
administration (days 28, 29, 30); (d) at T60, 1 month after the
last Lk administration (days 58, 59, 60).
The samples were collected by the owner immediately
after defecation, immediately stored at −20◦C in the owner’s
household freezer until delivered frozen to the department where
they were stored at−80◦C until use.
All the samples were analyzed for IgA detection, while, for the
gut microbiota, a pool of three samples from each dog at T0, T30,
and T60 was prepared and analyzed.
Fecal Microbiota Analysis
Microbial DNA was extracted from about 250mg of pooled fecal
sample, derived from the experimental points (T0; T30; T60) for
each dog, using the repeated bead-beating plus column method,
as previously described (27). Briefly, samples were suspended
in 1ml of lysis buffer (500mM NaCl, 50mM Tris-HCl, pH 8,
50mM EDTA, and 4% SDS) and bead-beaten three times in
a FastPrep instrument (MP Biomedicals, Irvine, CA, USA) at
5.5 movements/s for 1min, in the presence of four 3-mm glass
beads and 0.5 g of 0.1-mm zirconia beads (BioSpec Products,
Bartlesville, OK, USA). After incubation at 95◦C for 15min,
samples were centrifuged at 13,000 rpm for 5min. Two hundred
and sixty microliters of 10M ammonium acetate was added to
the supernatant, followed by 5-min incubation on ice and 10-
min centrifugation at 13,000 rpm. The supernatant was added
with one volume of isopropanol, followed by incubation on ice
for 30min. Precipitated nucleic acids were washed with 70%
ethanol, resuspended in 100µl of TE buffer, and treated with
2 µl of 10mg/ml DNase-free RNase at 37◦C for 15min. DNA
was further purified using the QIAamp Mini Spin columns
(QIAGEN, Hilden, Germany) following the manufacturer’s
instructions. DNA concentration and quality were evaluated
using the NanoDrop ND-1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA).
The V3–V4 hypervariable region of the 16S rRNA gene was
amplified by using the 341F and 785R primers with Illumina
adapter overhang sequences, as previously described (28). PCRs
were performed in a final volume of 25 µl, containing 12.5 ng
of genomic DNA, 200 nM of each primer, and 2X KAPA HiFi
HotStart ReadyMix (Kapa Biosystems, Wilmington, MA, USA),
in a Thermal Cycler T (Biometra GmbH, Göttingen, DE) with the
following thermal cycle: initial denaturation at 95◦C for 3min,
25 cycles of denaturation at 95◦C for 30 s, annealing at 55◦C for
30 s and extension at 72◦C for 30 s, and a final extension step
at 72◦C for 5min. Amplicons were purified using a magnetic
bead-based system (Agencourt AMPure XP; Beckman Coulter,
Brea, CA, USA). Indexed libraries were prepared by limited-cycle
PCR using Nextera technology and further purified as described
above. Final libraries were pooled at equimolar concentration,
denatured with 0.2N NaOH, and diluted to 6 pM before
loading onto the MiSeq flow cell. Sequencing was performed
on Illumina MiSeq platform with a 2 × 250 bp paired-end
protocol, according to the manufacturer’s instructions (Illumina,
San Diego, CA, USA).
Sequencing Reads Were Deposited in the National Center for
Biotechnology Information Sequence Read Archive (NCBI SRA;
BioProject ID PRJNA 592436).
Quantification of IgA Fecal Content
Stool samples were thawed and subsequently freeze-dried
(Modulyo EF4, 1044, Edwards, Apeldoorn, The Netherlands) for
16 h in order to eliminate the water contained and standardize
the subsequent analysis, as reported by Grellet et al. (29).
The lyophilized fecal samples were resuspended in 1X PBS
(phosphate buffer saline) containing 0.5% Tween20 (Sigma-
Aldrich, St. Louis, MO, USA), according to a weight/volume
ratio of 100 mg/ml (1:10 dilution) by vortex (3’) and then
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centrifuged at 1,500 × g for 10min. After removing the
supernatant, a further centrifugation was carried out at 10,000
× g for 20min, then the aqueous phase was taken and frozen at
−20◦C until the processing moment. The determination of the
IgA secretion amount was carried out by using a commercial
kit (dog IgA ELISA Quantitation Set, Bethyl Laboratories
Inc., TX, USA; Assay Range: 15.6–1,000 ng/ml), following the
manufacturer’s protocol.
Kefibios® Quality Control
In order to confirm the content of Lk declared by the
manufacturer, we performed an independent assessment of Lk
concentration in Kefibios R© capsules (Bacteriological Laboratory,
UNI EN ISO 9001:2015 registration number IT-15164).
Five different batches of the product, acquired in several
drugstores, with expiration date from 1 to 2 years with respect
to the time of the analysis, were analyzed, and enumeration of
viable bacteria was conducted by the plate count method.
Briefly, each sample was firstly solubilized in MRS Broth
(Oxoid CM359, Thermo Scientific, MA, USA) and gently shaken
at room temperature for 15min by using an orbital shaker, then
serially diluted in the same broth and inoculated onto MRS Agar
(Oxoid CM361, Thermo Scientific, MA, USA) plates. Plating was
performed in triplicate.
Plates were incubated at 37◦C for 72 h under anaerobic
atmosphere, and the number of colony-forming units (CFUs)
was determined.
The colonies obtained in the tests were identified by the API
50 CHL (BioMerieux, FI, Italy) test, and results are presented as
the number of viable cells per capsule and per dose (five drops).
Bioinformatics and Statistics
For the analysis of fecal microbiota composition and diversity,
raw sequences were processed using a pipeline combining
PANDAseq (30) and QIIME 1 (31). High-quality reads were
binned into operational taxonomic units (OTUs) through an
open-reference strategy at 0.97 similarity threshold by using
UCLUST (32). Taxonomy was assigned using the RDP classifier
and Greengenes as a reference database (release May 2013).
All singleton OTUs and chimeras, identified by ChimeraSlayer
(33), were discarded. Alpha rarefaction was performed using
observed OTUs, Shannon, and the phylogenetic diversity (PD)
whole tree metrics, while beta diversity was estimated by
computing weighted and unweighted UniFrac distances. For the
identification of Lk, OTUs assigned to the genus Lactobacillus
were subjected to BLAST analysis (34).
All statistical analyses were performed in R (version 3.1.3)
using the packages vegan, made4, and GraphPad Prism V.5.01
(GraphPad Software, La Jolla, CA, USA).
Assessment of data for normality was carried out by applying
the D’Agostino and Pearson Omnibus normality test.
UniFrac distances were used for principal coordinates analysis
(PCoA), and the significance of data separation was tested
using a permutation test with pseudo-F ratios (function Adonis
of vegan). Wilcoxon test for paired data was used to assess
significant differences in alpha diversity and taxon relative
abundance between groups.
A repeated-measures ANOVA (with Tukey post hoc test) was
applied to evaluate the differences in BW and fecal IgA content
between experimental points (T0, T15, T30, and T60). Friedman
test (with Dunn’s as post hoc test) was applied to evaluate the
differences in BCS and FSS between experimental points (T0,
T15, T30, and T60).
p < 0.05 was considered statistically significant.
RESULTS
Animals
Ten healthy adult dogs were included. Of those, one was male,
three neutered males, two females, and four neutered females.
Mean age was 4.9 ± 2.8 years (range 2–9). Breeds included were
mixed breed dogs (n = 4), Border Collies (n = 3), Labrador
Retriever (n = 1), Australian Shepherd (n = 1), and Dachshund
(n = 1). Their BW ranged from 5 to 33 kg (18.3 ± 9.84 kg),
while their average BCS was normal (range 4–6). Initial FSS was
normal in all dogs (range 2–3; Table 1). All dogs had normal
hematological and biochemical parameters, and the coprological
examination was negative for parasites.
The liquid product containing Lk was spontaneously accepted
by all the subjects. No clinical signs during the trial (with the
exception of dog #6), and up to 1 month later, were reported by
the owners.
There were no significant changes in BW and BCS during the
study period, nor did the FSS of each animal changed.
Dog #6 developed a urinary tract infection at day 50 of the trial
that required antibiotic treatment. This dog’s last fecal sample was
therefore excluded from the analysis.
Microbiota Analysis
A total of 1,536,903 high-quality reads (mean ± SD, 52,997
± 16,302) were obtained and clustered into 2,716 OTUs at
97% similarity.
The PCoA of intersample diversity based on weighted and
unweighted UniFrac distances showed no significant separation
among the study groups (i.e., baseline, end of treatment, and
follow-up; P = 0.7, permutation test with pseudo-F ratios;
Figure 1A). Similarly, no significant differences were found in
alpha diversity after Lk administration or in the follow-up
compared to the baseline (P > 0.05, Wilcoxon test; Figure 1B).
In line with the available literature on the gut microbiota
of healthy dogs (35, 36), the phylum-level microbial profiles at
the baseline were dominated by Firmicutes (relative abundance,
mean ± SEM, 73.1 ± 4.2%), with Actinobacteria (14.2 ±
3.1%), Bacteroidetes (7.8 ± 2.2%), and Fusobacteria (3.9
± 1.2%) as minor components (Figure 2). Lachnospiraceae,
Coriobacteriaceae, Clostridiaceae, and Erysipelotrichaceae were
the major families of the baseline microbiota (relative abundance
≥ 10%; Figure 3A). Consistently, the most represented genera
were Blautia, Clostridium, and Collinsella (Figure 3B). Following
Lk administration, no significant differences in taxon relative
abundance at these phylogenetic levels (i.e., phylum, family, and
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FIGURE 1 | Gut microbiota diversity of healthy dogs following Lk administration. (A) Principal coordinates analysis of intersample diversity, based on weighted (left)
and unweighted (right) UniFrac distances. (B) Alpha diversity computed with observed OTU metrics. T0, baseline; T30, after 30 days of Lk administration; T60, 1
month after the end of the treatment.
genus) were observed (Figures 2, 3). One month after the end of
the treatment, these changes were no longer detectable.
However, at T60, a decreasing trend in the relative abundances
of Fusobacteriaceae and Ruminococcaceae was found (T0 vs. T60,
P = 0.11 and 0.15, respectively; Figure 3A). With specific regard
to Lk, OTUs assigned to this species were not present at T0 but
accounted for 10.3% of Lactobacillus diversity (and 0.07% of the
intestinal ecosystem) after 30 days of Lk administration, which
then disappear again in the follow-up.
IgA Content in Fecal Samples
A total of 117 fecal samples were taken and analyzed. Three
samples (T58, T59, and T60 from dog #6) were missing because
dog #6 was excluded from the trial.
The water content of feces was very similar among all the
samples with percentage values of 38.08± 4.97 (mean± SD).
IgA was detected in all samples except for sample T15 from
dog #3 (undetectable < 15.6 ng/ml). All dogs have shown a huge
intra-individual variability of fecal IgA content among the three
following day samples at T0, T15, T30, and T60 (Figure 4A).
Only in four dogs it was possible to observe an increasing
trend in the IgA fecal content (dogs 1, 2, 3, and 6; Figure 4A).
In Figure 4B, we showed a ratio between the quantity of IgA
fecal content at T15, T30, and T60 and the basal (T0) for each dog.
Overall, the fecal IgA content between different time points
did not show any significant differences (p= 0.1; Figure 5).
Kefibios® Quality Control
The number of viable Lk per capsule from different product
batches varied from 7.73 × 107 CFU to 152 × 107 CFU (81 ±
61× 107 CFU, mean and standard deviation).
The number of viable Lk in the liquid formulation per dose
of five drops varied from 0.39 × 107 CFU to 7.55 × 107 CFU
(3.2± 2.4× 107 CFU, mean and standard deviation) and was
hence 2-log fold lower than the declared concentration (≥109
CFU) by the company.
DISCUSSION
In recent years, interest in characterizing the canine intestinal
microbiota has soared, and therapeutical interventions that can
positively influence the microbiota composition and function,
specifically identification of novel probiotics, are sought (2, 3, 37).
Several potential probiotics have already been tested in
dogs, including bacterial species belonging to the genera
Enterococcus, Lactobacillus, Bifidobacterium, and Saccharomyces,
demonstrating their role in the treatment of acute and chronic
enteropathies (15–18, 38–40).
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FIGURE 2 | Impact of Lk administration on the phylum-level compositional structure of the gut microbiota of healthy dogs. Top: pie charts of mean values of relative
abundance; Bottom: bar plots of individual profiles. T0, baseline; T30, after 30 days of Lk administration; T60, 1 month after the end of the treatment.
Among Lactobacillus strain, several species have been already
studied (Lactobacillus acidophilus DSM13241; Lactobacillus
fermentumCCM7421; Lactobacillus animalis LA4). However, the
achieved results are difficult to compare as different dosages (107
CFU/daily dose; 109 CFU/daily dose; 3 to 3.6 × 109 CFU/daily
dose) and different forms of application were used, and the
duration of administration was also variable (15, 17, 18).
To date, no studies have evaluated the influence of Lk on the
parameters of intestinal health in dogs.
Only one previous study has assessed the effect of kefir
(a fermented dairy product containing Lk) on dogs (21).
This study demonstrated a significant increase in the fecal
LAB:Enterobacteriaceae ratio and a decrease in the fecal
Firmicutes:Bacteroidetes ratio, which was interpreted as an
improvement of the gut microbiota composition. However, this
study did not use a single bacterial strain, but the mixture of more
than 50 microorganisms contained in kefir, and only reported a
dose for total LAB (9.32± 0.23 log10 CFU/ml) and yeast (7.12±
0.36 log10 CFU/ml) (21). It is therefore difficult to calculate and
compare the precise concentration of Lk that was administered
in this study, and to infer the changes observed to a single
potentially probiotic strain, as it could be attributed to several
microorganisms and their potential synergism.
In addition, the composition of microorganisms in kefir
may vary depending on its origin, the substrate used in the
fermentation process, and the culturemaintenancemethods (41).
The product used in our study is a commercial preparation
registered as a probiotic for human medicine, containing Lk
with 30-day stability of reconstituted product guaranteed by
the producer. Currently, there are no recommendations for the
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FIGURE 3 | Impact of Lk administration on the family- and genus-level compositional structure of the gut microbiota of healthy dogs. Relative abundance profiles at
family (A) and genus (B) level. Top: pie charts of mean values; bottom: bar plots of individual profiles. T0, baseline; T30, after 30 days of Lk administration; T60, 1
month after the end of the treatment.
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FIGURE 4 | (A) Fecal IgA content at different time points (T0; T15; T30; T60); each value (mean ± SD) represents the average of the measurements of the three
samples collected in three consecutive days for each experimental point: T0, before the administration, T15 and T30, after 15 and 30 days of Lk administration; and
T60, 1 month after the last Lk administration. The T60 fecal samples of dog #6 were excluded from the analysis due to antibiotic therapy. (B) IgA fecal content
evaluated by the ratio between the quantity at T15, T30, and T60 and the basal (T0) for each dog.
dosage of Lk in dogs. Daily dosages used in mice and people were
108 and 1010 CFU, respectively (24, 26).
The dose administered to dogs in the present study was
extrapolated from the dose for an adult person as recommended
by the manufacturer. While the daily dose for people (five drops)
should contain ≥109 AFUs of live and viable Lk, the results
presented here indicate that the same dose, administered to the
dogs of this study, was more equal to 3.2± 2.4× 107 CFU.
The 30-day duration of the experiment was chosen based on
available literature and a suspected washout time of 4 weeks after
discontinuation of administration (42).
Fecal samples were chosen over other types of samples to
evaluate the intestinal microbiota, as they can be collected in a
noninvasive manner, raising no ethical concerns in comparison
to, for example, intestinal mucosal biopsies. In addition, the
ability of Lk to modulate microbiota composition has already
been demonstrated using fecal samples in people and mice (25,
26). Similarly, concentrations of IgA from duodenal biopsies and
fecal samples showed no difference in a previous study (4).
As for the gut microbiota, in line with what has already been
reported for probiotic supplementations in healthy individuals
(43), no changes were detected after Lk administration.
The IgA results showed a large interdog variability at T0 (from
1.33 to 35.35 mg/g of dehydrated feces), which, although all
dogs appeared clinically healthy, could depend on the extreme
variability in experimental dogs’ signaling, age, life environment,
and food taken.
Moreover, our IgA variability is in agreement with the data
reported by other authors (29, 44).
Regardless of the basal value, we have noted the
absence of a significant variation in the fecal IgA content
comparing the experimental time points, i.e., pretreatment
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FIGURE 5 | Fecal IgA content at different time points (T0; T15; T30; T60) in
dogs included in the trial (mean ± SD). No significant statistical differences
were observed (p = 0.1).
(T0), during (T15 and T30), and 30 days after Lk
administration (T60).
Possible explanation of the results could be related
to a poor immunomodulatory effect of Lk toward the
canine GALT (gut associated lymphoid tissue) due to (a)
poor LK viability in pharmaceuticals administered and
consequent insufficient probiotic dose; (b) inadequate
administration period; and (c) poor vitality in the
gastrointestinal tract of the dog with lack of Lk probiotic activity
in dogs.
Considering the first point, the differences found between
the concentration declared by the company (Lk ≥ 25 × 109
AFU/capsule; ≥ 109 AFU/dose) and that found in our quality
control analysis (81 ± 61 × 107 CFU/capsule; 3.2 ± 2.4 × 107
CFU/dose) must be emphasized.
It must be stressed that the gap between what was
declared by the probiotic company and what was highlighted
by an independent analysis is not a rare event. In fact,
analyzing the literature, numerous papers, both in the
field of human and veterinary medicine, evidence this
gap, with several-folds reduction of live probiotics
concentration with respect to which reported by the
companies (45–47).
Though not much is known about the minimal dose and/or
frequency of probiotics required for the probiotic effect, it seems
to be dose-dependent (48). For this reason, it cannot be excluded
that the absence of changes observed in fecal microbiota and
IgA during the trial with Lk can be attributed to an insufficient
dosage, corresponding to ∼3% of the expected dose indicated
for humans.
It is also true that an improvement in the enteric immune
function in dogs was observed even after the administration of
Lactobacillus fermentum at the dosage of 1 × 107 CFU/daily
dose for 1 week, similar dose, and lower trial time, than the one
actually used by us (18).
With respect to the treatment time, our study treatment
is longer than employed in similar studies (15–17), with
two intratreatment withdrawals in addition to pre- and post-
treatment sampling, so this point can be excluded as a cause of
poor response too.
Lastly, no previous studies have analyzed the Lk vitality in the
canine gastrointestinal tract; therefore, it cannot be excluded that
this may be the cause of the poor probiotic activity observed in
our study.
Conversely, studies performed in human medicine have
verified the gastrointestinal Lk vitality showing a high rate of
adhesion of Lk to intestinal cells and strong resistance to gastric
juice and intestinal bile salts (49).
Limitations of the study include the fact that dogs
did not receive a uniform diet during the experiment,
and the relatively low number of dogs included,
further confounded by the exclusion of dog #6 from
the analysis.
However, we believe that not artificially standardizing the
dogs’ diet might allow for results to be translated easier into real-
life veterinary practice conditions and would showcase that Lk is
able to impact the microbiota independent of the diet given. We
also believe that our methods of analysis will, to a certain degree,
be able to counteract any dietary effect, as the dogs could serve as
their own controls.
With respect to the sample size, the current study is similar to
other feeding trials performing similar analyses (15–18).
In conclusion, our study was unable to demonstrate a
significant change in microbiota composition or function in
healthy dogs administered with Lk at a dose of 3.2 ± 2.4 × 107
CFU/daily dose for 30 days. Further research will be necessary in
order to assess the efficacy of a higher dose or of the combination
of Lk with other potential probiotics.
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